Critical review of guidelines for BPH diagnosis and treatment strategy

European Urology, Supplements

Volumn 5, Issue 4 SPEC. ISS., 2006, Pages 418-429

  Novara, Giacomo ^a   Galfano, Antonio ^a   Gardi, Mario ^a   Ficarra, Vincenzo ^b   Boccon Gibod, Laurent ^c   Artibani, Walter ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY OF VERONA   (Italy)

^c BICHAT HOSPITAL   (France)

Author keywords

AUA; BAUS; Benign prostate hyperplasia; Clinical practice guidelines; Dutasteride; EAU; Evidence based medicine; Finasteride; Lower urinary tract symptoms; Minimally invasive therapy; Phytotherapy; Postvoiding residual urine; Prostatectomy; PSA; Blockers

Indexed keywords

ALFUZOSIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; DOXAZOSIN; DUTASTERIDE; FINASTERIDE; PHENOXYBENZAMINE; PRAZOSIN; PYGEUM AFRICANUM EXTRACT; SABAL EXTRACT; STEROID 5ALPHA REDUCTASE INHIBITOR; TAMSULOSIN; TERAZOSIN;

ASTHENIA; CLINICAL TRIAL; DIZZINESS; EJACULATION DISORDER; ERECTILE DYSFUNCTION; FATIGUE; HIGH INTENSITY FOCUSED ULTRASOUND; HUMAN; LASER COAGULATION; LIBIDO DISORDER; MEDICAL SOCIETY; META ANALYSIS; MINIMALLY INVASIVE SURGERY; NOSE CONGESTION; ORTHOSTATIC HYPOTENSION; PHYTOTHERAPY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; REVIEW; SCORING SYSTEM; SYSTEMATIC REVIEW; TRANSURETHRAL MICROWAVE THERMOTHERAPY; TRANSURETHRAL NEEDLE ABLATION; URINARY TRACT INFECTION; URINE RETENTION;

EID: 33644750449     PISSN: 15699056     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eursup.2006.02.005     Document Type: Article

References (50)

1. D.L. Sackett, W.M.C. Rosenberg, J.A. Muir Gray, R.B. Haynes, and Y. Scott Richardson Evidence based medicine: what it is and what it isn't BMJ 12 1996 1 2
2. Evidence-based medicine A new approach to teaching the practice of medicine. Evidence-Based Medicine Working Group JAMA 268 1992 2420 2425
3. M. Emberton Clinical practice guidelines for the surgeon-how should they be understood and applied? BJU Int 88 2001 485 492
4. K.N. Lohr, and M.J. Field A provisional instrument for assessing clinical practice guidelines M.J. Field K.N. Lohr Guidelines for clinical practice. From development to use 1992 National Academy Press Washington, DC 346 410
5. T.M. Shaneyfelt, M.F. Mayo-Smith, and J. Rothwangl Are guidelines following guidelines? The methodological quality of clinical practice guidelines in the peer-reviewed medical literature JAMA 281 1999 1900 1905
6. R. Grilli, N. Magrini, A. Penna, G. Mura, and A. Liberati Practice guidelines developed by specialty societies: the need for a critical appraisal Lancet 355 2000 103 106
7. NHS, Executive Clinical guidelines 1996 NHSE Leeds, United Kingdom
8. F.A. Cluzeau, and P. Littlejohns Appraising clinical practice guidelines in England and Wales. The development of a methodologic framework and its application to policy Jt Comm J Qual Improv 25 1999 514 521
9. The AGREE Collaboration Development and validation of an international appraisal instrument for assessing the quality of clinical practice guidelines: the AGREE project Qual Safety Health Care 12 2003 18 23
10. P. Abrams Ner words for old: lower urinary tract symptoms for "prostatism" BMJ 308 1994 929 930
11. C. Chatelain L. Denis J.K.T. Foo al. et Fifth International Consultation on Benign Prostatic Hyperplasia 2001 Health Publications Plymouth, United Kingdom
12. H.M. Arrighi, E.J. Metter, H.A. Guess, and J.L. Fozzard Natural history of benign prostatic hyperplasia and risk of prostatectomy, the Baltimore Longitudinal Study of Aging Urology 35 1991 4 8
13. C.G. Chute, L.A. Panser, and C.J. Girman The prevalence of prostatism: a population based survey of urinary symptoms J Urol 150 1993 85 89
14. R.R. Berges, and L. Pientka Management of the BPH syndrome in Germany: who is treated and how? Eur Urol 36 1999 21 27
15. S. Madersbacher, G. Alivizatos, J. Nordling, C.R. Sanz, M. Emberton, and J.J. de la Rosette EAU 2004 guidelines on assessment, therapy and follow-up of men with lower urinary tract symptoms suggestive of benign prostatic obstruction (BPH guidelines) Eur Urol 46 2004 547 554
16. AUA Practice Guidelines Committee AUA guideline on management of benign prostatic hyperplasia. Diagnosis and treatment recommendations J Urol 70 2003 530 547
17. Clinical Practice Guidelines. The management of uncomplicated lower urinary tract symptoms in men. National Health and Medical Research Council, 2000.
18. M.J. Speakman, R.S. Kirby, A. Joyce, P. Abrams, and R. Pocock The British Association of Urological Surgeons. Guideline for the primary care management of male lower urinary tract symptoms BJU Int 93 2004 985 990
19. J.C. Nickel, S. Herschorn, and J. Corcos Canadian Urological Association Guidelines Committee. Canadian guidelines for the management of benign prostatic hyperplasia Can J Urol 12 2005 2677 2683
20. A.T. Cockett, Y. Aso, and L. Denis World Health Organization Consensus Committee recommendations concerning the diagnosis of BPH Prog Urol 1 1991 957 972
21. Phillips B, Ball C, Sackett D, et al. Levels of evidence and grades of recommendation. Oxford Centre for Evidence-Based Medicine, http://www.cebm.net/ levels_of_evidence.asp#levels.
22. J.L.H.R. Bosch, A.M. Bohnen, and F.P.M.J. Groeneveld Validity of digital rectal examination and serum prostate specific antigen in the estimation of prostate volume in community-based men aged 50 to 78 years: the Krimpen study Eur Urol 46 2004 753 759
23. C.J. Girman, S.J. Jacobsen, and T. Rhodes Prostate size related to urinary symptoms and health related quality of life in randomly selected men J Urol 157 1997 193
24. A.L. Poulsen, J. Schou, L. Puggaard, S. Torpedersen, and J. Nordling Prostatic enlargement, symptomatology, and pressure/flow evaluation: interrelations in patients with symptomatic BPH Scand J Nephrol 157 1994 67 73
25. K.M. Jensen, J.B. Jorgensen, and P. Mogensen Urodynamics in prostatism. I. Prognostic value of uroflowmetry Scand J Nephrol 22 1998 109 117
26. C. Manieri, S.S. Carter, G. Romano, A. Trucchi, M. Valenti, and A. Tubaro The diagnosis of bladder outlet obstruction in men by ultrasound measurement of bladder wall thickness J Urol 159 1998 761 765
27. J. Nordling Altering disease progression: the key to successful patient management BJU Int 93 2004 16 20
28. C.G. Roehrborn, A. Prajsner, R. Kirby, M. Andersen, S. Quinn, and S. Mallen A double-blind placebo-controlled study evaluating the onset of action of doxazosin gastrointestinal therapeutic system in the treatment of benign prostatic hyperplasia Eur Urol 48 2005 445 452
29. R.C. Rosen, F. Giuliano, and C.C. Carson Sexual dysfunction and lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) Eur Urol 47 2005 824 837
30. A.R. Zlotta, P. Teillac, J.P. Raynaud, and C.C. Schulman Evaluation of male sexual function in patients with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) treated with a phytotherapeutic agent (Permixon), tamsulosin or finasteride Eur Urol 48 2005 269 276
31. K.T. McVary Erectile dysfunction and lower urinary tract symptoms secondary to BPH Eur Urol 47 2005 838 845
32. J.D. McConnell, R. Bruskewitz, and P. Walsh The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia N Engl J Med 338 1998 557 563
33. J.D. McConnell, C.G. Roehrborn, and O.M. Bautista The long-term effect of doxazosin, finasteride, and combination therapy on the progression of benign prostatic hyperplasia N Engl J Med 349 2003 2387 2398
34. C.G. Roehrborn, P. Boyle, J.C. Nickel, K. Hoefner, G. Andriole ARIA3001 ARIA3002 and ARIA3003 Study Investigators Efficacy and safety of dual inhibitor of 5-alpha reductase type 1 and 2 (dutasteride) in men with benign prostatic hyperplasia Urology 60 2000 434 441
35. F. Debruyne, J. Barkin, J. van Erps, M. Reis, T.L.J. Tammela, C. Roehrborn on behalf of the ARIA3001, ARIA3002, ARIB3003 Study Investigators Efficacy and safety of long-term treatment with the dual 5a-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia Eur Urol 46 2004 488 495
36. M. Marberger, R. Harkaway, and J. de la Rosette Optimising the medical management of benign prostatic hyperplasia Eur Urol 45 2004 411 419
37. T.J. Wilt, A. Ishani, I. Rutks, and R. MacDonald Phytotherapy for benign prostatic hyperplasia Public Health Nutr 3 2000 459 472
38. P. Boyle, C. Robertson, F. Lowe, and C. Roehrborn Updated meta-analysis of clinical trials of Serenoa repens extract in the treatment of symptomatic benign prostatic hyperplasia BJU Int 93 2004 751 756
39. A.R. Zlotta, and B. Djavan Minimally invasive therapies for benign prostatic hyperplasia in the new millennium: long-term data Curr Opin Urol 12 2002 7 14
40. J. Irani, C.T. Brown, J. Van der Meulen, and M. Emberton A review of guidelines on benign prostatic hyperplasia and lower urinary tract symptoms: are all guidelines the same? BJU Int 92 2003 937 942
41. C.G. Roehrborn, J.D. McConnell, and M. Lieber Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. PLESS Study Group Urology 53 1999 473 480
42. C.G. Roehrborn, P. Boyle, and D. Bergner Serum prostate-specific antigen and prostate volume predict long-term changes in symptoms and flow rate: results of a 4-year, randomized trial comparing finasteride versus placebo. PLESS Study Group Urology 54 1999 662 669
43. C.G. Roehrborn, J. McConnell, and J. Bonilla Serum prostate specific antigen is a strong predictor of future prostate growth in men with benign prostatic hyperplasia. PROSCAR long-term efficacy and safety study J Urol 163 2000 13 20
44. C.G. Roehrborn The potential of serum prostate-specific antigen as a predictor of clinical response in patients with lower urinary tract symptoms and benign prostatic hyperplasia BJU Int 93 2004 21 26
45. G. Bartsch, J.M. Fitzpatrick, J.A. Schalken, J. Isaacs, J. Nordling, and C.G. Roehrborn Consensus statement: the role of prostate-specific antigen in managing the patient with benign prostatic hyperplasia BJU Int 93 2004 27 29
46. A. Tubaro, C. La Vecchia Uroscreening Study Group The relation of lower urinary tract symptoms with life-style factors and objective measures of benign prostatic enlargement and obstruction: an Italian survey Eur Urol 45 2004 767 772
47. I.M. Thompson, P.J. Goodman, and C.M. Tangen The influence of finasteride on the development of prostate cancer N Engl J Med 349 2003 215 224
48. J.Y. Lee, H.W. Kim, J.S. Kohn, H.J. Suh, and M.B. Chancellor Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder BJU Int 94 2004 817 820
49. A. Athanasopoulos, K. Gyftopoulos, K. Giannitsas, J. Fisfis, P. Perimenis, and G. Barbalias Combination treatment with an alpha-blocker plus an anticholinergic for bladder outlet obstruction: a prospective, randomized, controlled study J Urol 169 2003 2253 2256
50. K.E. Andersson Antimuscarinics for treatment of overactive bladder Lancet Neurol 3 2004 46 53